98%
921
2 minutes
20
The contribution of anticholinergic burden to cognitive function in patients with treatment resistant schizophrenia (TRS) is uncertain. This case-control study aims to comprehensively examine the association between treatment resistance and cognitive functions and the contribution of anticholinergic burden in patients with schizophrenia. Anticholinergic burden of all patients was calculated using the Anticholinergic Cognitive Burden scale. Exploratory Factor Analysis of 11 cognitive assessments identified four cognitive domains: verbal memory, attention and general cognitive functions, visual memory and processing speed, and executive function. Two structural equation models (SEM) examined the relationship of TRS and these cognitive functions with, and without considering anticholinergic burden. A total of 288 participants were included (TRS N=111, non-TRS N=177). Patients with TRS performed poorer than the non-TRS group only in the executive function domain. Anticholinergic burden contributed significantly to the attention and general cognitive functions, visual memory and processing speed, and executive function. The impact of TRS on executive function was no longer significant after adding anticholinergic burden to the SEM. Results suggested that anticholinergic burden contributes to a wide range of cognitive function impairment in patients with schizophrenia and is likely to be part of the apparent differences of cognitive function between TRS and non-TRS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2024.115985 | DOI Listing |
Neurol Ther
September 2025
Dayton Psychiatric Associations, Dayton, OH, USA.
Introduction: Tardive dyskinesia (TD), a persistent and often debilitating movement disorder, is associated with prolonged exposure to dopamine receptor-blocking agents. Individuals aged ≥ 60 years are at increased risk for TD and TD-related burden (e.g.
View Article and Find Full Text PDFDement Neuropsychol
August 2025
Hospital Santa Marcelina, São Paulo SP, Brazil.
Unlabelled: Anticholinergic burden (ACB) and polypharmacy are poorly studied in the context of primary care in Brazil.
Objective: To evaluate the ACB and polypharmacy of individuals with suspected dementia referred from primary care to tertiary dementia outpatient clinics in Brazil.
Methods: We performed a cross-sectional study in two tertiary dementia clinics.
J Spinal Cord Med
September 2025
Department of Physical Medicine and Rehabilitation, Ankara City Hospital, Ankara, Turkey.
Context: Individuals with suprasacral spinal cord injury (SCI) often face significant clinical and quality-of-life (QoL) burdens due to neurogenic detrusor overactivity (NDO). Transcutaneous tibial nerve stimulation (TTNS) is a non-invasive neuromodulation technique that may serve as a treatment option, but evidence regarding its effectiveness in anticholinergic-refractory NDO remains limited.
Objectives: To evaluate the effectiveness of TTNS on urodynamic parameters in individuals with SCI who have anticholinergic-refractory NDO.
Basic Clin Pharmacol Toxicol
October 2025
Faculty of Medicine, University of Southampton, Southampton, UK.
Background: Anticholinergic medication use is increasing, particularly among older adults due to polypharmacy and comorbidities. High anticholinergic burden is linked to adverse outcomes such as reduced mobility and increased dementia risk. Acute hospital stays may offer an opportunity to address this often-overlooked issue.
View Article and Find Full Text PDFBr J Clin Pharmacol
August 2025
Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Medication review in the hospital is an effective tool for identifying inappropriate prescribing, but not every patient can receive one due to resource constraints. Thus, it is important to identify patients who stand to benefit most from medication review. Patients are typically identified for medication review based on number of medications and age, but this may not be the most efficient strategy for identifying patients at high risk of future adverse clinical outcomes.
View Article and Find Full Text PDF